All Stories

  1. Critical role of the finger loop in arrestin binding to the receptors
  2. Heterologous phosphorylation-induced formation of a stability lock permits regulation of inactive receptors by β-arrestins
  3. Differential manipulation of arrestin-3 binding to basal and agonist-activated G protein-coupled receptors
  4. Beyond traditional pharmacology: new tools and approaches
  5. GRK3 suppresses L-DOPA-induced dyskinesia in the rat model of Parkinson’s disease via its RGS homology domain
  6. How genetic errors in GPCRs affect their function: Possible therapeutic strategies
  7. C-terminal threonines and serines play distinct roles in the desensitization of rhodopsin, a G protein-coupled receptor
  8. GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1–2 September 2014
  9. G Protein-coupled Receptor Kinases of the GRK4 Protein Subfamily Phosphorylate Inactive G Protein-coupled Receptors (GPCRs)
  10. Arrestins
  11. The Rhodopsin-Arrestin-1 Interaction in Bicelles
  12. Arrestins regulate cell spreading and motility via focal adhesion dynamics
  13. Arrestin Expression inE. coliand Purification
  14. Overview of Different Mechanisms of Arrestin-Mediated Signaling
  15. Imaging visual arrestin in vivo
  16. Peptide Modifications Differentially Alter G Protein-Coupled Receptor Internalization and Signaling Bias
  17. Mutations in arrestin-3 differentially affect binding to neuropeptide Y receptor subtypes
  18. Identification of Receptor Binding-induced Conformational Changes in Non-visual Arrestins
  19. Arrestin-3 binds the MAP kinase JNK3α2 via multiple sites on both domains
  20. Extensive shape shifting underlies functional versatility of arrestins
  21. Arrestin makes T cells stop and become active
  22. Arrestins - Pharmacology and Therapeutic Potential
  23. Rapid degeneration of rod photoreceptors expressing self-association-deficient arrestin-1 mutant
  24. Arrestin-3 Binds c-Jun N-terminal Kinase 1 (JNK1) and JNK2 and Facilitates the Activation of These Ubiquitous JNK Isoforms in Cells via Scaffolding
  25. Arrestins in Apoptosis
  26. Arrestin-Dependent Activation of JNK Family Kinases
  27. Enhanced Phosphorylation-Independent Arrestins and Gene Therapy
  28. Self-Association of Arrestin Family Members
  29. Targeting Individual GPCRs with Redesigned Nonvisual Arrestins
  30. Therapeutic Potential of Small Molecules and Engineered Proteins
  31. Constitutively active rhodopsin mutants causing night blindness are effectively phosphorylated by GRKs but differ in arrestin-1 binding
  32. Caspase-cleaved arrestin-2 and BID cooperatively facilitate cytochrome C release and cell death
  33. JNK3 Enzyme Binding to Arrestin-3 Differentially Affects the Recruitment of Upstream Mitogen-activated Protein (MAP) Kinase Kinases
  34. Visual arrestin interaction with clathrin adaptor AP-2 regulates photoreceptor survival in the vertebrate retina
  35. Insights into congenital stationary night blindness based on the structure of G90D rhodopsin
  36. Critical Role of the Central 139-Loop in Stability and Binding Selectivity of Arrestin-1
  37. Structural Determinants of Arrestin Functions
  38. Involvement of distinct arrestin-1 elements in binding to different functional forms of rhodopsin
  39. Engineering Visual Arrestin-1 with Special Functional Characteristics
  40. Identification of phosphorylation sites in the COOH‐terminal tail of the μ‐opioid receptor
  41. Ligand Directed Signaling Differences between Rodent and Human κ-Opioid Receptors
  42. Conformation of receptor-bound visual arrestin
  43. Synthetic biology with surgical precision: Targeted reengineering of signaling proteins
  44. Manipulation of Very Few Receptor Discriminator Residues Greatly Enhances Receptor Specificity of Non-visual Arrestins
  45. Silent Scaffolds
  46. The Origin and Evolution of G Protein-Coupled Receptor Kinases
  47. ßarrestin1-biased agonism at human δ-opioid receptor by peptidic and alkaloid ligands
  48. Role of Receptor-attached Phosphates in Binding of Visual and Non-visual Arrestins to G Protein-coupled Receptors
  49. G protein-coupled receptor kinases: More than just kinases and not only for GPCRs
  50. The Effect of Arrestin Conformation on the Recruitment of c-Raf1, MEK1, and ERK1/2 Activation
  51. Nonvisual Arrestins Function as Simple Scaffolds Assembling the MKK4–JNK3α2 Signaling Complex
  52. The functional cycle of visual arrestins in photoreceptor cells
  53. Reduced expression of G protein-coupled receptor kinases in schizophrenia but not in schizoaffective disorder
  54. A Single Mutation in Arrestin-2 Prevents ERK1/2 Activation by Reducing c-Raf1 Binding
  55. Progressive Reduction of its Expression in Rods Reveals Two Pools of Arrestin-1 in the Outer Segment with Different Roles in Photoresponse Recovery
  56. Identification of Arrestin-3-specific Residues Necessary for JNK3 Kinase Activation
  57. Ubiquitin Ligase Parkin Promotes Mdm2–Arrestin Interaction but Inhibits Arrestin Ubiquitination
  58. Identification of key factors that reduce the variability of the single photon response
  59. Few Residues within an Extensive Binding Interface Drive Receptor Interaction and Determine the Specificity of Arrestin Proteins
  60. Robust Self-Association Is a Common Feature of Mammalian Visual Arrestin-1
  61. Crystal Structure of Arrestin-3 Reveals the Basis of the Difference in Receptor Binding Between Two Non-visual Subtypes
  62. Arrestin-1 expression level in rods: balancing functional performance and photoreceptor health
  63. Kinetics of Rhodopsin Deactivation and Its Role in Regulating Recovery and Reproducibility of Rod Photoresponse
  64. Elucidation of Inositol Hexaphosphate and Heparin Interaction Sites and Conformational Changes in Arrestin-1 by Solution Nuclear Magnetic Resonance
  65. Monomeric Rhodopsin Is Sufficient for Normal Rhodopsin Kinase (GRK1) Phosphorylation and Arrestin-1 Binding
  66. Ligand-induced Internalization and Recycling of the Human Neuropeptide Y2Receptor Is Regulated by Its Carboxyl-terminal Tail
  67. Lentiviral Overexpression of GRK6 Alleviates L-Dopa-Induced Dyskinesia in Experimental Parkinson's Disease
  68. Custom-designed proteins as novel therapeutic tools? The case of arrestins
  69. Non-visual Arrestins Are Constitutively Associated with the Centrosome and Regulate Centrosome Function
  70. The Role of Arrestin α-Helix I in Receptor Binding
  71. Dynamics of mouse rod phototransduction and its sensitivity to variation of key parameters
  72. Enhanced Arrestin Facilitates Recovery and Protects Rods Lacking Rhodopsin Phosphorylation
  73. Enhanced Arrestin Facilitates Recovery and Protects Rods Lacking Rhodopsin Phosphorylation
  74. Altered Sensitivity to Rewarding and Aversive Drugs in Mice with Inducible Disruption of cAMP Response Element-Binding Protein Function within the Nucleus Accumbens
  75. Overexpression of Rhodopsin Alters the Structure and Photoresponse of Rod Photoreceptors
  76. How Does Arrestin Assemble MAPKs into a Signaling Complex?
  77. An Intracellular Loop 2 Amino Acid Residue Determines Differential Binding of Arrestin to the Dopamine D2 and D3 Receptors
  78. A Dopamine D2 Receptor Mutant Capable of G Protein-Mediated Signaling but Deficient in Arrestin Binding
  79. Structure and Function of the Third Intracellular Loop of the 5-Hydroxytryptamine2A Receptor: The Third Intracellular Loop Is α-Helical and Binds Purified Arrestins
  80. A Model for the Solution Structure of the Rod Arrestin Tetramer
  81. Rich Tapestry of G Protein-Coupled Receptor Signaling and Regulatory Mechanisms
  82. How and why do GPCRs dimerize?
  83. Diffusion of the Second Messengers in the Cytoplasm Acts as a Variability Suppressor of the Single Photon Response in Vertebrate Phototransduction
  84. Arrestins and two receptor kinases are upregulated in Parkinson's disease with dementia
  85. GPCR monomers and oligomers: it takes all kinds
  86. Haloperidol and Clozapine Differentially Affect the Expression of Arrestins, Receptor Kinases, and Extracellular Signal-Regulated Kinase Activation
  87. Opposing Effects of Inositol Hexakisphosphate on Rod Arrestin and Arrestin2 Self-Association†
  88. Altered expression and subcellular distribution of GRK subtypes in the dopamine-depleted rat basal ganglia is not normalized by l-DOPA treatment
  89. Cone arrestin binding to JNK3 and Mdm2: conformational preference and localization of interaction sites
  90. Regulation of Arrestin Binding by Rhodopsin Phosphorylation Level
  91. Anesthetic considerations during percutaneous nephrolithotomy
  92. Functional Comparisons of Visual Arrestins in Rod Photoreceptors of Transgenic Mice
  93. Arrestin Mobilizes Signaling Proteins to the Cytoskeleton and Redirects their Activity
  94. Structure and function of the visual arrestin oligomer
  95. Each rhodopsin molecule binds its own arrestin
  96. Arrestin Binding to Calmodulin: A Direct Interaction Between Two Ubiquitous Signaling Proteins
  97. The structural basis of arrestin-mediated regulation of G-protein-coupled receptors
  98. Visual and Both Non-visual Arrestins in Their “Inactive” Conformation Bind JNK3 and Mdm2 and Relocalize Them from the Nucleus to the Cytoplasm
  99. Soluble Mimics of the Cytoplasmic Face of the Human V1-Vascular Vasopressin Receptor Bind Arrestin2 and Calmodulin
  100. Differential interaction of spin-labeled arrestin with inactive and active phosphorhodopsin
  101. Visual Arrestin Binding to Microtubules Involves a Distinct Conformational Change
  102. The Differential Engagement of Arrestin Surface Charges by the Various Functional Forms of the Receptor
  103. Crystal Structure of Cone Arrestin at 2.3Å: Evolution of Receptor Specificity
  104. Conformational Differences Between Arrestin2 and Pre-activated Mutants as Revealed by Hydrogen Exchange Mass Spectrometry
  105. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors
  106. Light-Dependent Redistribution of Arrestin in Vertebrate Rods Is an Energy-Independent Process Governed by Protein-Protein Interactions
  107. Dopamine D1 receptor interaction with arrestin3 in neostriatal neurons
  108. Calmodulin kinase II inhibition protects against structural heart disease
  109. l-DOPA reverses the MPTP-induced elevation of the arrestin2 and GRK6 expression and enhanced ERK activation in monkey brain
  110. Arrestin2 expression selectively increases during neural differentiation
  111. Inhibition of Chemoattractant N-Formyl Peptide Receptor Trafficking by Active Arrestins
  112. Preferential Interaction between the Dopamine D2 Receptor and Arrestin2 in Neostriatal Neurons
  113. Direct Binding of Visual Arrestin to Microtubules Determines the Differential Subcellular Localization of Its Splice Variants in Rod Photoreceptors
  114. The molecular acrobatics of arrestin activation
  115. Mapping the Arrestin-Receptor Interface
  116. The New Face of Active Receptor Bound Arrestin Attracts New Partners
  117. Functional Capabilities of anN-Formyl Peptide Receptor−Gαi2Fusion Protein:  Assemblies with G Proteins and Arrestins†
  118. The Interaction of a Constitutively Active Arrestin with the Arrestin-Insensitive 5-HT2A Receptor Induces Agonist-Independent Internalization
  119. The interaction with the cytoplasmic loops of rhodopsin plays a crucial role in arrestin activation and binding
  120. The Nature of the Arrestin·Receptor Complex Determines the Ultimate Fate of the Internalized Receptor
  121. N -Formyl Peptide Receptor Phosphorylation Domains Differentially Regulate Arrestin and Agonist Affinity
  122. Transition of Arrestin into the Active Receptor-binding State Requires an Extended Interdomain Hinge
  123. The Third Intracellular Loop of α2-Adrenergic Receptors Determines Subtype Specificity of Arrestin Interaction
  124. ARF6: a newly appreciated player in G protein-coupled receptor desensitization
  125. Aspartic Acid 564 in the Third Cytoplasmic Loop of the Luteinizing Hormone/Choriogonadotropin Receptor Is Crucial for Phosphorylation-independent Interaction with Arrestin2
  126. μ-Opioid Receptors Desensitize Less Rapidly than δ-Opioid Receptors Due to Less Efficient Activation of Arrestin
  127. Arrestin2 and arrestin3 are differentially expressed in the rat brain during postnatal development
  128. Conservation of the Phosphate-sensitive Elements in the Arrestin Family of Proteins
  129. Arrestin Variants Display Differential Binding Characteristics for the PhosphorylatedN-Formyl Peptide Receptor Carboxyl Terminus
  130. Partial Phosphorylation of theN-Formyl Peptide Receptor Inhibits G Protein Association Independent of Arrestin Binding
  131. Regulation of Formyl Peptide Receptor Agonist Affinity by Reconstitution with Arrestins and Heterotrimeric G Proteins
  132. Crystal Structure of β-Arrestin at 1.9 Å
  133. Real-time Analysis of G Protein-coupled Receptor Reconstitution in a Solubilized System
  134. Threonine 180 Is Required for G-protein-coupled Receptor Kinase 3- and β-Arrestin 2-mediated Desensitization of the μ-Opioid Receptor inXenopusOocytes
  135. An Additional Phosphate-binding Element in Arrestin Molecule
  136. Conserved Phosphoprotein Interaction Motif Is Functionally Interchangeable between Ataxin-7 and Arrestins †
  137. The ADP ribosylation factor nucleotide exchange factor ARNO promotes β-arrestin release necessary for luteinizing hormone/choriogonadotropin receptor desensitization
  138. Arrestin Binding to the M2Muscarinic Acetylcholine Receptor Is Precluded by an Inhibitory Element in the Third Intracellular Loop of the Receptor
  139. Visual Arrestin Activity May Be Regulated by Self-association
  140. β-Arrestin-dependent Desensitization of Luteinizing Hormone/Choriogonadotropin Receptor Is Prevented by a Synthetic Peptide Corresponding to the Third Intracellular Loop of the Receptor
  141. How Does Arrestin Respond to the Phosphorylated State of Rhodopsin?
  142. A Model for Arrestin’s Regulation: The 2.8 Å Crystal Structure of Visual Arrestin
  143. Targeted Construction of Phosphorylation-independent β-Arrestin Mutants with Constitutive Activity in Cells
  144. A direct role for arrestins in desensitization of the luteinizing hormone/choriogonadotropin receptor in porcine ovarian follicular membranes
  145. Molecular events associated with the regulation of signaling by M2 muscarinic receptors
  146. The Selectivity of Visual Arrestin for Light-activated Phosphorhodopsin Is Controlled by Multiple Nonredundant Mechanisms
  147. Agonist-Receptor-Arrestin, an Alternative Ternary Complex with High Agonist Affinity
  148. Internalization of the m2 Muscarinic Acetylcholine Receptor
  149. Mechanism of Quenching of Phototransduction
  150. Arrestin/Clathrin Interaction
  151. Arrestin with a Single Amino Acid Substitution Quenches Light-Activated Rhodopsin in a Phosphorylation-Independent Fashion†
  152. Role of Arrestins in G-Protein-Coupled Receptor Endocytosis
  153. β-Arrestin acts as a clathrin adaptor in endocytosis of the β2-adrenergic receptor
  154. [21] Use of bacteriophage RNA polymerase in RNA synthesis
  155. Visual Arrestin Binding to Rhodopsin
  156. In Vitro Transcription: Preparative RNA Yields in Analytical Scale Reactions
  157. Preparative in vitro mRNA synthesis using SP6 and T7 RNA polymerases
  158. Functional expression in vitro of bovine visual rhodopsin
  159. In vitro synthesis of visual rhodopsin for a protein engineering study